复发性儿科急性肝衰竭的表型和长期结果:系统性审查和个人参与者数据分析
Harry Sutton1, Or Steg Saban1, Jessie Cunningham2
1Division of Gastroenterology Hepatology and Nutrition, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
概括
儿童的重复性急性肝衰竭 (RALF),通常与遗传突变有关,通常在婴儿期出现,并可能自发消失. 对于不明原因的病例,建议对NBAS,SCYL1,RINT1和LARS1进行基因检测.
科学领域:
- 儿科肝病学 儿科肝病学
- 临床遗传学 临床遗传学
- 基因组医学是基因组医学.
背景情况:
- 儿童的重复性急性肝衰竭 (RALF) 涉及多次肝衰竭,在事件之间完全恢复.
- 在NBAS,RINT1,LARS1和SCYL1中的基因突变与RALF有关.
- 了解移植和死亡率对于管理儿科RALF至关重要.
研究的目的:
- 系统地审查和分析特定基因突变的儿童RALF的个体患者数据.
- 在这个患者群体中确定移植和死亡率.
- 为管理儿科RALF的临床决策提供信息.
主要方法:
- 系统审查和一个阶段的个人参与者分析.
- 在EMBASE,MEDLINE和Web of Science中搜索到2025年5月14日之前的英语研究.
- 包括对患有NBAS,RINT1,LARS1或SCYL1突变的儿科RALF的研究.
主要成果:
- 确定了168名RALF患者,中位数是9个月的第一次呈现.
- 最常见的突变基因是NBAS (66%) 和LARS1 (18.4%).
- 11%的人接受了肝移植,17.3%的人死亡;移植后没有出现复发.
结论:
- 儿童的RALF通常在生命的第一年出现,并且可以有自我限制的过程,经常由发烧性疾病引发.
- 对RALF的肝移植是有争议的,对于随着年龄的增长而消失的疾病可能不太适用.
- 推针对NBAS,SCYL1,RINT1和LARS1的整体外组测序,用于发烧儿童的不明原因急性肝衰竭.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
179
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
179
Pharmacokinetics in Pediatric Patients: Drug Metabolism
189
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
189
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
210
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
210
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
240
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
240
Chronic Pancreatitis II: Collaborative Care
307
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
307
Acute Kidney Injury IV: Diagnostic Studies and Prevention
256
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
256


